Stock Movers After FDA (FRX, MNKD, RDY, CYTX, RGEN)

Forest Laboratories Inc (NYSE:FRX) slipped to 0.28% to $31.79.

Scottsdale, AZ (prHWY.com) January 24, 2011 - Forest Laboratories Inc (NYSE:FRX) slipped to 0.28% to $31.79. The Company along with Pierre Fabre Medicament announced preliminary top-line results from Phase III study of levomilnacipran for the treatment of major depressive disorder.

MannKind Corporation (NASDAQ:MNKD) is one of the top losers. The stock went down 42.92% to $5.20 after the Company failed to win approval from U.S. regulators to market its first product for diabetes called Afrezza.

Dr. Reddy's Laboratories Limited (ADR) (NYSE:RDY) declined 0.6% to $36.49. The Company has launched Pantoprazole Sodium Delayed-Released tablets in the US market. FDA approved Dr. Reddy's ANDA for Pantoprazole Sodium Delayed-Released tablets on January 19, 2011.

Cytori Therapeutics Inc (USA) (NASDAQ:CYTX) is down 2.71% to $5.39.The Company has received approval from The Netherlands to initiate a pivotal European trial, named ADVANCE in the treatment of patients with acute heart attacks.

Repligen Corporation (NASDAQ:RGEN) soared 3.14% to $4.93 after the Company entered into an exclusive license agreement with the University of California for a patent application covering the use of histone deacetylase 3.Continue @ http://www.collegestock.com/blog/736-stock-movers-after-fda-frx-mnkd-rdy-cytx-rgen/

Our College stock website highlights penny stocks to buy as well as best stocks to invest in.

###

Tag Words: penny stock investing, penny stocks newsletters, penny stock investments

Categories: Investment

Press Release Contact
7161 E. Rancho Vista Dr.
Scottsdale, AZ 85251

Link To This Press Release:

URL HTML Code